Nasal Preparations
Introduction The intranasal route has been exploited for the management of localized symptoms associated with allergic rhinitis, nasal congestion and nasal infection, as well as for the delivery of drugs to the systemic circulation . In 2019, FDA approves Spravato (esketamine) nasal spray for treatment-resistant depression. NOTE: Although intranasal drug delivery for systemic activity avoids hepatic first-pass metabolism of oral route and may be associated with rapid absorption and onset of action, it is limited by Small delivery volumes, therefore potent drugs are required. Mucociliary clearance and/or barrier by mucus decrease absorption of some drugs Enzymatic activity (pseudo first-pass effect) Low epithelial permeability for hydrophilic drugs; absorption enhances and/or large doses are required. Drug Delivery Currently, delivery devices are usually metered-dose manual pump sprays , because they are cheap, robust and reliable, but more sophisticated systems are now under develop...